{"id":"non-statin-lipid-modifying-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Elevated uric acid levels"},{"rate":null,"effect":"Gout"},{"rate":null,"effect":"Injection site reactions (if injectable formulation)"},{"rate":null,"effect":"Influenza-like symptoms"}]},"_chembl":{"chemblId":"CHEMBL3354642","moleculeType":"Small molecule","molecularWeight":"1826.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This category encompasses multiple drug classes including PCSK9 inhibitors, bempedoic acid, inclisiran, and other agents that target different steps in lipid metabolism. They may work by enhancing LDL receptor expression, inhibiting uric acid production coupled with lipid reduction, or silencing PCSK9 gene expression to lower LDL cholesterol and improve cardiovascular outcomes in patients who cannot tolerate or are inadequately controlled on statins.","oneSentence":"Non-statin lipid-modifying therapies work through alternative pathways to reduce cholesterol and triglycerides without inhibiting HMG-CoA reductase.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:23:15.179Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperlipidemia / dyslipidemia management"},{"name":"Cardiovascular risk reduction in statin-intolerant or inadequately controlled patients"}]},"trialDetails":[{"nctId":"NCT02666664","phase":"PHASE3","title":"Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2016-01-21","conditions":"Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases","enrollment":2230},{"nctId":"NCT02988115","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2016-11-16","conditions":"Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Statin Adverse Reaction","enrollment":345},{"nctId":"NCT00687076","phase":"PHASE4","title":"Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2004-04","conditions":"Peripheral Arterial Disease","enrollment":102},{"nctId":"NCT02715726","phase":"PHASE3","title":"Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-07-27","conditions":"Hypercholesterolemia","enrollment":615},{"nctId":"NCT02984982","phase":"PHASE4","title":"Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-11-15","conditions":"Hypercholesterolemia, Acute Coronary Syndrome","enrollment":206},{"nctId":"NCT02584504","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11-30","conditions":"Hypercholesterolemia","enrollment":163},{"nctId":"NCT02023879","phase":"PHASE3","title":"Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-12-16","conditions":"Hypercholesterolemia","enrollment":233},{"nctId":"NCT02585778","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-10-23","conditions":"Hypercholesterolaemia","enrollment":517},{"nctId":"NCT02642159","phase":"PHASE4","title":"Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-03-15","conditions":"Dyslipidemia","enrollment":413},{"nctId":"NCT02289963","phase":"PHASE3","title":"Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01","conditions":"Hypercholesterolemia","enrollment":199},{"nctId":"NCT02107898","phase":"PHASE3","title":"Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-03","conditions":"Hypercholesterolemia","enrollment":216},{"nctId":"NCT01644188","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-08","conditions":"Hypercholesterolemia","enrollment":720},{"nctId":"NCT01623115","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-07","conditions":"Hypercholesterolemia","enrollment":486},{"nctId":"NCT01507831","phase":"PHASE3","title":"Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-01","conditions":"Hypercholesterolemia","enrollment":2341},{"nctId":"NCT01644175","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-07","conditions":"Hypercholesterolemia","enrollment":316},{"nctId":"NCT01709500","phase":"PHASE3","title":"Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-12","conditions":"Heterozygous Familial Hypercholesterolemia","enrollment":249}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Non-statin Lipid-Modifying Therapy","genericName":"Non-statin Lipid-Modifying Therapy","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Non-statin lipid-modifying therapies work through alternative pathways to reduce cholesterol and triglycerides without inhibiting HMG-CoA reductase. Used for Hyperlipidemia / dyslipidemia management, Cardiovascular risk reduction in statin-intolerant or inadequately controlled patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}